XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Expense and Related Income Tax Benefit Stock-based compensation expense by statement of operations caption and the related income tax benefit were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Cost of sales$25 $32 $72 $94 
Research and development expenses198 283 571 817 
Selling, general and administrative expenses:
Employees
1,321 1,726 4,076 5,398 
Outside directors
107 94 296 524 
Total employee and director stock-based compensation expense$1,651 $2,135 $5,015 $6,833 
Income tax benefit$255 $326 $762 $1,073 
Non-Vested Restricted Stock Award Activity
Non-vested restricted stock award activity was as follows:
Shares
(in thousands)		Weighted-Average Grant Date Fair Value
Non-vested at December 31, 2023
486 $21.66 
Granted355 10.46 
Vested(242)25.11 
Forfeited(18)16.40 
Non-vested at September 30, 2024
581 $13.51 
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award
Non-vested performance stock award activity was as follows:
Shares
(in thousands)		Weighted-Average Grant Date Fair Value
Non-vested at December 31, 2023
— $— 
Granted116 4.72 
Vested— — 
Forfeited— — 
Non-vested at September 30, 2024
116 $4.72 
The assumptions we utilized in the Monte Carlo simulation model and the resulting weighted average fair value of performance stock grants were the following:
 Three Months Ended September 30,Nine Months Ended September 30,
 20242024
Weighted average fair value of grants$— $4.72 
Risk-free interest rate— %4.08 %
Expected volatility— %57.00 %
Expected life in years0.002.73
Stock Option Activity
Stock option activity was as follows:    
Number of Options
(in thousands)		Weighted-Average Exercise PriceWeighted-Average Remaining Contractual Term
(in years)		Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 2023
901 $38.78 
Granted— — 
Exercised— — $— 
Forfeited/canceled/expired(122)58.52 
Outstanding at September 30, 2024 (1)
779 $35.67 3.37$— 
Vested and expected to vest at September 30, 2024 (1)
779 $35.67 3.37$— 
Exercisable at September 30, 2024 (1)
646 $37.63 2.96$— 
(1)The aggregate intrinsic value represents the total pre-tax value (the difference between our closing stock price on the last trading day of the third quarter of 2024 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had they all exercised their options on September 30, 2024. This amount will change based on the fair market value of our stock.
Assumptions Used in Valuation and Weighted Average Fair Value of Stock Option Grants
The assumptions we utilized in the Black-Scholes option pricing model and the resulting weighted average fair value of stock option grants were the following:
 Three Months Ended September 30,Nine Months Ended September 30,
 20232023
Weighted average fair value of grants$— $10.83 
Risk-free interest rate— %3.86 %
Expected volatility— %45.89 %
Expected life in years0.004.70